Matches in Nanopublications for { ?s ?p "[Additionally, results from a Phase I trial of MEHD7495A, a dual-action antibody that blocks ligand binding to EGFR and HER3, suggest that high-level HRG expression was associated with clinical response in SCCHN patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_assertion description "[Additionally, results from a Phase I trial of MEHD7495A, a dual-action antibody that blocks ligand binding to EGFR and HER3, suggest that high-level HRG expression was associated with clinical response in SCCHN patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP337390.RAnDKCGYuCzbD-X_10slgJqlALyMPRFoZd4-hVDtt3hWM130_provenance.